Telogen EffluviumNCT07433933
Clinical Study to Evaluate Effect of Shampoo in Subjects With Hair Loss.
An observational study of Telogen Effluvium and Androgenetic Alopecia, run by Lacer S.A. at 1 site in Spain.
Trial summary
The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia (AGA). Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Telogen Effluvium, Androgenetic Alopecia
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteSpain
- Study dates
- 12 May 2025to 16 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Clinic database
Who may be able to join
- Sex: Both (50% women; 50% men).
- Age: 18-65 years.
- Subjects with hair loss due to telogen effluvium or mild or incipient androgenic alopecia, in an 80/20 ratio.
- Degree of androgenic alopecia: Ludwig scale score I-II for women and Hamilton-Norwood scale score III-II for men.
- Telogen effluvium: Combing test.
- Subjects with all hair types (oily, combination, sensitive, etc.).
Show all 12Show fewer
- Subjects with all scalp types (normal, sensitive, etc.).
- Agree to participate voluntarily in the study and provide written informed consent.
- Adequate level of understanding of the clinical study.
- Good health (physical and mental).
- Availability to attend visits to the research centres.
- No application of any product to the experimental area on the first day of the trial.
Who cannot join
- Individuals under 18 years of age.
- Pregnant or breastfeeding women.
- Injuries or infection in the test area.
- History of allergies to cosmetic products.
- Known allergies to product components.
- Sensitivity to any product component.
Show all 12Show fewer
- Patients who have undergone recent surgery or treatments in the study area.
- Cancer patients.
- Volunteers currently taking antibiotics, antihistamines, corticosteroids, beta-blockers, retinoids, azelaic acid, or acne therapies, or whose treatment ended within 15 days prior to the start of the study. Participation in another clinical study.
- Use of or having used cosmetic products and/or oral or topical treatments for hair loss for at least 6 months.
- Hair cutting or dyeing during the study.
- Health problems, to be assessed by the specialist, that may compromise adherence to the study protocol.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Centro Médico Complutense Grupo Virtus
Alcalá de Henares, Madrid, 28805
About this study
Official title: Clinical Study to Evaluate the Efficacy and Safety of a Cosmetic Product in Subjects With Telogen Effluvium and Androgenic Alopecia
The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia (AGA). The main question it aims to answer is:
- Does a shampoo use help to reduce the visible signs of hair loss related to TE and AGA?
Subjects will use the shampoo for 3 months and visit the clinic for the visits established by the protocol.
- Conditions
- Telogen Effluvium, Androgenetic Alopecia
- Being tested
- anti-hair loss shampoo
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
anti-hair loss shampooOther
anti-hair loss shampoo use for 3 months
| Study group | Role | What they receive |
|---|---|---|
| anti-hair loss shampoo | Not described Receives: Other: anti-hair loss shampoo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in hair lenght and thickness
Measured: From baseline to the end of use at 3 months.
Secondary outcomes (1)
Change in hair lenght and thickness at 1 month
Measured: Baseline and 1 month of use
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start12 May 2025
- Primary completion16 Oct 2025
- Study completion16 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Telogen EffluviumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lacer S.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07433933
- Sponsor's protocol ID
- LACER_2406_COS
- Status last verified
- Feb 2026
- First submitted
- 19 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Only summary of the results to support the publication will be shared. No complete study documents will shared.
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study to Evaluate the Efficacy and Safety of a Cosmetic Product in Subjects With Telogen Effluvium and Androgenic Alopecia
- ClinicalTrials.gov ID
- NCT07433933
- Acronym / sponsor ID
- LACER_2406_COS
- Conditions
- Telogen Effluvium, Androgenetic Alopecia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Lacer S.A.Industry (pharma, biotech, devices)
- Study start
- 12 May 2025 (actual)
- Primary completion
- 16 Oct 2025 (actual)
- Study completion
- 16 Oct 2025 (actual)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the effects of anti-hair loss shampoo in subjects over the age of 18 who use shampoo to treat their hair loss caused by telogen effluvium (TE) and androgenetic alopecia (AGA). The main question it aims to answer is:
- Does a shampoo use help to reduce the visible signs of hair loss related to TE and AGA?
Subjects will use the shampoo for 3 months and visit the clinic for the visits established by the protocol.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| anti-hair loss shampoo | – | Other: anti-hair loss shampoo |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Clinic database
Key inclusion criteria (12 listed)
- Sex: Both (50% women; 50% men).
- Age: 18-65 years.
- Subjects with hair loss due to telogen effluvium or mild or incipient androgenic alopecia, in an 80/20 ratio.
- Degree of androgenic alopecia: Ludwig scale score I-II for women and Hamilton-Norwood scale score III-II for men.
- Telogen effluvium: Combing test.
Key exclusion criteria (12 listed)
- Individuals under 18 years of age.
- Pregnant or breastfeeding women.
- Injuries or infection in the test area.
- History of allergies to cosmetic products.
- Known allergies to product components.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| anti-hair loss shampooanti-hair loss shampoo use for 3 months | Other | anti-hair loss shampoo |
Primary outcome
Change in hair lenght and thickness
Time frame: From baseline to the end of use at 3 months.
1 secondary outcome
Change in hair lenght and thickness at 1 month
Time frame: Baseline and 1 month of use
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: No. Only summary of the results to support the publication will be shared. No complete study documents will shared.
Related trials for Telogen Effluvium
Not yet recruitingObservational study
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Gut Dysbiosis, Telogen Effluvium
Recruiting
Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists
Telogen Effluvium
Not yet recruiting
Evaluation of the Dietary Supplement Effect on Improvement of Hair Condition in Subjects With Occasional Hair Loss.
Occasional Hair Loss
Not yet recruiting
Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use
Alopecia
Not yet recruitingPhase 2/3
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Telogen Effluvium, Female Pattern Hair Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Telogen Effluvium and Androgenetic Alopecia, run by Lacer S.A. at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in hair lenght and thickness (time frame: From baseline to the end of use at 3 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.